Go Pro
OTCMKTS:MRMD

MariMed (MRMD) Stock Price, News & Analysis

MariMed logo
$0.06 0.00 (-6.19%)
As of 07/30/2026 03:44 PM Eastern

About MariMed Stock (OTCMKTS:MRMD)

Advanced

Key Stats

Today's Range
$0.06
$0.07
50-Day Range
$0.06
$0.08
52-Week Range
$0.06
$0.23
Volume
194,538 shs
Average Volume
232,118 shs
Market Capitalization
$25.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

MariMed Inc. is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs. MariMed’s proprietary formulations are developed in its research and development labs, where it focuses on dosing consistency, terpene profiles and potency control. In addition to in‐house brands such as Nature’s Heritage and Lowell Farms, MariMed supplies white‐label products for third‐party operators and manages state‐licensed manufacturing facilities on behalf of other cannabis companies.

MariMed’s operations span multiple state markets, including Massachusetts, Maryland, Illinois, and Pennsylvania, where it holds cultivation and processing licenses as well as retail dispensary permits. The company’s retail banners, notably Zen Leaf, serve adult‐use and medical patients with a curated selection of cannabis products and patient education services. By aligning its facility design, cultivation practices and product offerings with state regulatory requirements, MariMed strives to maintain compliance while scaling its footprint in high‐growth cannabis markets.

Founded in 2011 by chief executive officer Bob Fireman, MariMed leverages more than a decade of experience in life‐science research, pharmaceutical formulation and regulated consumer products. Under Fireman’s leadership, the company has built a vertically integrated platform that emphasizes quality assurance, regulatory compliance and community engagement. MariMed Inc. trades on the OTC Markets under the ticker symbol MRMD and continues to pursue new licensing opportunities and strategic collaborations to broaden its cannabis enterprise.

AI Generated. May Contain Errors.

MariMed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

MRMD MarketRank™: 

MariMed scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MariMed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MariMed has received no research coverage in the past 90 days.

  • Read more about MariMed's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MariMed is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MariMed is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MariMed has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MariMed's valuation and earnings.
  • Percentage of Shares Shorted

    0.00% of the float of MariMed has been sold short.
  • Short Interest Ratio / Days to Cover

    MariMed has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MariMed has recently increased by 108.63%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MariMed does not currently pay a dividend.

  • Dividend Growth

    MariMed does not have a long track record of dividend growth.

  • News Sentiment

    MariMed has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for MariMed this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for MRMD on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MariMed insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.29% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    0.18% of the stock of MariMed is held by institutions.

  • Read more about MariMed's insider trading history.
Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRMD Stock News Headlines

MariMed Inc. (OTCMKTS:MRMD) Short Interest Update
MariMed Announces Second Quarter 2026 Earnings Date
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
See More Headlines

MRMD Stock Analysis - Frequently Asked Questions

MariMed's stock was trading at $0.0879 at the beginning of the year. Since then, MRMD stock has decreased by 27.6% and is now trading at $0.0636.

MariMed Inc. (OTCMKTS:MRMD) posted its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). The firm earned $39.48 million during the quarter, compared to the consensus estimate of $38.75 million. MariMed had a negative trailing twelve-month return on equity of 5.00% and a negative net margin of 7.82%.
Read the conference call transcript
.

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MariMed investors own include Canopy Growth (CGC), Innovative Industrial Properties (IIPR), NVIDIA (NVDA), Curaleaf (CURLF), Aurora Cannabis (ACB), Meta Platforms (META) and Tilray Brands (TLRY).

Company Calendar

Last Earnings
5/13/2026
Today
7/31/2026
Next Earnings (Estimated)
8/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:MRMD
Previous Symbol
OTC:MRMD
CIK
1522767
Fax
N/A
Employees
260
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.48 million
Net Margins
-7.82%
Pretax Margin
-5.78%
Return on Equity
-5.00%
Return on Assets
-1.29%

Debt

Debt-to-Equity Ratio
1.67
Current Ratio
0.95
Quick Ratio
0.34

Sales & Book Value

Annual Sales
$159.83 million
Price / Sales
0.16
Cash Flow
$0.02 per share
Price / Cash Flow
2.93
Book Value
$0.13 per share
Price / Book
0.49

Miscellaneous

Outstanding Shares
401,167,000
Free Float
331,805,000
Market Cap
$25.51 million
Optionable
Not Optionable
Beta
1.32
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (OTCMKTS:MRMD) was last updated on 7/31/2026 by MarketBeat.com Staff.
From Our Partners